

Clínica Baviera, S.A.
CIF A80240427
Paseo de la Castellana, 20
28046 Madrid

Spanish Securities Market Commission

Edison, 4
28006 Madrid

Dear Sirs,

For the purposes of article 227 of the consolidated text of the Spanish Securities Market Law, approved by Royal Legislative Decree 4/2015, of October 23, I hereby disclose the following

Other Relevant Information

Further to the notification of the relevant fact communication dated April 8, 2017 (registry no. 250,551) in respect of the public tender offer over the shares of Clínica Baviera, S.A. (the “**Company**”), carried out by Aier Eye International (Europe), S.L.U. (“**Aier Europe**”) authorised on June 27, 2017 (the “**Offer**”), the Company hereby discloses that it has been informed today that (i) Aier Europe, (ii) Aier Eye Hospital Group Co, Ltd. (“**Aier Eye**”), (iii) Aier Eye International (Hong Kong) Limited (“**Aier Hong Kong**” together with Aier Europe and Aier Eye, the “**Aier Group**”) and (iv) Vito Gestión Patrimonial, S.L. (“**Vito Gestión**”), have entered into a partial termination agreement with respect to the Put and Call Option Agreement executed on April 7, 2017 and referred to in such relevant fact communication (the “**Partial Termination Agreement**” and the “**Agreement**”).

Among others, under the Agreement (i) Vito Gestión and the Aier Group reciprocally granted certain crossed put and call options with respect to 1,630,758 shares of the Company, owned by Vito Gestión, representing 10% of the Company's share capital (the “**Shares**”); (ii) a lock-up agreement on the Shares for a period of 3 years after the settlement of the Offer was regulated; (iii) tag and drag along rights on the Shares were established; and (iv) a right of first refusal over the Shares in favor of Aier Europe was provided.

Pursuant to such Partial Termination Agreement (i) the crossed put and call options over the abovementioned shares are terminated and cancelled, (ii) the right of first refusal over the Shares in

favour of Aier Europe is terminated and cancelled, (iii) Shares representing 2% of the Company's share capital are released from any transfer restrictions under the Agreement –namely tag-along and drag-along rights– and, (iv) the remaining provisions of the Agreement remain in full force and effect.

Madrid, November 26, 2020

Antonio Peral Ortiz de la Torre

Secretary to the Board of Directors